Healthequity (NASDAQ:HQY) was downgraded by investment analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Wednesday.
A number of other equities research analysts also recently weighed in on HQY. Zacks Investment Research downgraded shares of Healthequity from a “buy” rating to a “hold” rating in a research note on Tuesday, November 20th. BidaskClub downgraded shares of Healthequity from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 13th. Oppenheimer raised their price objective on shares of Healthequity from $85.00 to $104.00 and gave the company an “outperform” rating in a report on Wednesday, September 5th. Barrington Research reiterated an “outperform” rating and issued a $100.00 price objective on shares of Healthequity in a report on Wednesday, September 5th. They noted that the move was a valuation call. Finally, Wells Fargo & Co raised their price objective on shares of Healthequity from $84.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, September 5th. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $92.08.
HQY opened at $74.03 on Wednesday. Healthequity has a 1-year low of $42.92 and a 1-year high of $101.58. The company has a market capitalization of $5.19 billion, a PE ratio of 137.09, a P/E/G ratio of 2.90 and a beta of 1.37.
Healthequity (NASDAQ:HQY) last posted its quarterly earnings results on Tuesday, December 4th. The company reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of $0.20 by $0.02. Healthequity had a net margin of 24.52% and a return on equity of 12.93%. The company had revenue of $70.50 million for the quarter, compared to the consensus estimate of $69.60 million. During the same period last year, the company posted $0.17 EPS. The firm’s quarterly revenue was up 24.1% compared to the same quarter last year. Sell-side analysts anticipate that Healthequity will post 0.87 earnings per share for the current year.
In related news, VP Darcy G. Mott sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, October 22nd. The shares were sold at an average price of $87.01, for a total value of $348,040.00. Following the completion of the transaction, the vice president now owns 92,500 shares in the company, valued at approximately $8,048,425. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In the last quarter, insiders sold 12,000 shares of company stock valued at $1,027,400. 4.00% of the stock is owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in HQY. Advisors Asset Management Inc. raised its holdings in Healthequity by 5,212.2% during the 2nd quarter. Advisors Asset Management Inc. now owns 72,086 shares of the company’s stock worth $160,000 after purchasing an additional 70,729 shares during the last quarter. Meeder Asset Management Inc. bought a new position in Healthequity during the 3rd quarter worth approximately $172,000. Cerebellum GP LLC bought a new position in Healthequity during the 3rd quarter worth approximately $185,000. Sawtooth Solutions LLC bought a new position in Healthequity during the 2nd quarter worth approximately $207,000. Finally, Cambridge Investment Research Advisors Inc. bought a new position in Healthequity during the 3rd quarter worth approximately $210,000. Hedge funds and other institutional investors own 93.01% of the company’s stock.
Healthequity Company Profile
HealthEquity, Inc provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company offers healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Read More: How can investors find ex-dividend dates?
To view ValuEngine’s full report, visit ValuEngine’s official website.